[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100653340":3},{"organization":4,"outcomesModule":7,"designInfo":44,"detailedDescription":43,"studyPopulation":43,"armGroups":50,"interventions":63,"overallOfficials":73,"centralContacts":77,"locations":83,"responsibleParty":101,"collaborators":43,"id":103,"slug":104,"hasResults":105,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":43,"eligibilityCriteria":109,"healthyVolunteers":110,"sex":111,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":43,"studyType":117,"phases":118,"briefSummary":120,"conditions":121,"keywords":43,"overallStatus":123,"whyStopped":43,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":43},[9,13],{"measure":10,"description":11,"timeFrame":12},"Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Rosuvastatin When MK-4646 is Coadministered with Rosuvastatin","Blood samples will be collected to determine the AUC0-Inf of rosuvastatin when MK-4646 is coadministered with rosuvastatin.","At designated timepoints (up to approximately 72 hours post dose)",{"measure":14,"description":15,"timeFrame":12},"Maximum Plasma Concentration (Cmax) of Rosuvastatin When MK-4646 is Coadministered with Rosuvastatin","Blood samples will be collected to determine the Cmax of rosuvastatin when MK-4646 is coadministered with rosuvastatin.",[17,21,25,28,31,34,37,40],{"measure":18,"description":19,"timeFrame":20},"Number of Participants Who Experience an Adverse Event (AE)","An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.","Up to approximately 26 days",{"measure":22,"description":23,"timeFrame":24},"Number of Participants Who Discontinue Study Treatment Due to an AE","An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.","Up to approximately 9 days",{"measure":26,"description":27,"timeFrame":12},"Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-last) of Rosuvastatin When MK-4646 is Coadministered with Rosuvastatin","Blood samples will be collected to determine the AUC0-last of rosuvastatin when MK-4646 is coadministered with rosuvastatin.",{"measure":29,"description":30,"timeFrame":12},"Area Under the Concentration-Time Curve from Time 0 to 24 (AUC0-24) of Rosuvastatin When MK-4646 is Coadministered with Rosuvastatin","Blood samples will be collected to determine the AUC0-24 of rosuvastatin when MK-4646 is coadministered with rosuvastatin.",{"measure":32,"description":33,"timeFrame":12},"Time to Maximum Plasma Concentration (Tmax) of Rosuvastatin When MK-4646 is Coadministered with Rosuvastatin","Blood samples will be collected to determine the Tmax of rosuvastatin when MK-4646 is coadministered with rosuvastatin.",{"measure":35,"description":36,"timeFrame":12},"Apparent Terminal Half-life (t½) of Rosuvastatin When MK-4646 is Coadministered with Rosuvastatin","Blood samples will be collected to determine the t½ of rosuvastatin when MK-4646 is coadministered with rosuvastatin.",{"measure":38,"description":39,"timeFrame":12},"Apparent Clearance (CL\u002FF) of Rosuvastatin When MK-4646 is Coadministered with Rosuvastatin","Blood samples will be collected to determine the CL\u002FF of rosuvastatin when MK-4646 is coadministered with rosuvastatin.",{"measure":41,"description":42,"timeFrame":12},"Apparent Volume of Distribution (Vz\u002FF) of Rosuvastatin When MK-4646 is Coadministered with Rosuvastatin","Blood samples will be collected to determine the Vz\u002FF of rosuvastatin when MK-4646 is coadministered with rosuvastatin.",null,{"allocation":45,"interventionModel":46,"interventionModelDescription":43,"primaryPurpose":47,"observationalModel":43,"timePerspective":43,"maskingInfo":48},"RANDOMIZED","CROSSOVER","BASIC_SCIENCE",{"masking":49,"maskingDescription":43,"whoMasked":43},"NONE",[51,57],{"label":52,"type":53,"description":54,"interventionNames":55},"Treatment A: Rosuvastatin","ACTIVE_COMPARATOR","Participants will receive a single oral dose of rosuvastatin.",[56],"Drug: Rosuvastatin",{"label":58,"type":59,"description":60,"interventionNames":61},"Treatment B: Rosuvastatin + MK-4646","EXPERIMENTAL","Participants will receive a single oral dose of rosuvastatin coadministered with MK-4646.",[56,62],"Drug: MK-4646",[64,69],{"type":65,"name":66,"description":67,"armGroupLabels":68,"otherNames":43},"DRUG","Rosuvastatin","Oral tablet",[52,58],{"type":65,"name":70,"description":71,"armGroupLabels":72,"otherNames":43},"MK-4646","Oral capsule",[58],[74],{"name":75,"affiliation":5,"role":76},"Medical Director","STUDY_DIRECTOR",[78],{"name":79,"role":80,"phone":81,"phoneExt":43,"email":82},"Toll Free Number","CONTACT","1-888-577-8839","Trialsites@merck.com",[84],{"facility":85,"status":43,"city":86,"state":87,"zip":88,"country":89,"countryCode":90,"cosmosGeoPoint":91,"geoPoint":96,"contacts":97},"QPS-MRA, LLC ( Site 0002)","South Miami","Florida","33143","United States","US",{"type":92,"coordinates":93},"Point",[94,95],-80.29338,25.7076,{"lat":95,"lon":94},[98],{"name":99,"role":80,"phone":100,"phoneExt":43,"email":43},"Study Coordinator","305-598-3125",{"type":102,"investigatorFullName":43,"investigatorTitle":43,"investigatorAffiliation":43,"oldNameTitle":43,"oldOrganization":43},"SPONSOR","100653340","phase-1-a-clinical-trial-to-evaluate-the-effects-of-mk-4646-on-rosuvastatin-in-healthy-participants-mk-4646-007-100653340",false,"NCT07785830","A Clinical Trial to Evaluate the Effects of MK-4646 on Rosuvastatin in Healthy Participants (MK-4646-007)","An Open-Label, Crossover Study to Evaluate the Effects of a Single Dose of MK-4646 on Single Dose Pharmacokinetics of Rosuvastatin in Healthy Participants","Inclusion Criteria:\n\n* Is in good health before randomization\n* Has a body mass index (BMI) between 18 and 32 kg\u002Fm\\^2, inclusive\n\nExclusion Criteria:\n\n* Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases\n* Has a history of cancer (malignancy)\n* Has a history or presence of myopathy or rhabdomyolysis (with or without prior statin therapy)",true,"ALL","18 Years","60 Years",{"count":115,"type":116},16,"ESTIMATED","INTERVENTIONAL",[119],"PHASE1","Researchers are looking for new treatments for people living with HIV-1 (Human Immunodeficiency Virus Type 1). HIV-1 is the most common type of HIV, which is a virus that attacks cells of the immune system.\n\nMK-4646 is a trial medicine designed to treat HIV-1. Before giving a trial medicine to people with a health condition, researchers first do studies in healthy participants.\n\nThe goals of this trial are to learn:\n\n* What happens to rosuvastatin in a participant's body over time when it is taken with MK-4646\n* About the safety of MK-4646 when taken with rosuvastatin and if people tolerate it. Tolerate means participants will receive trial medicine in the trial unless they need to stop it due to health problems.",[122],"Healthy","NOT_YET_RECRUITING","2026-10-02",{"date":126,"type":127},"2026-10-05","ACTUAL",{"date":129,"type":116},"2026-09-25",{"date":131,"type":116},"2026-11-10",{"name":5,"class":6},1]